Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study
/PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive top-line results from the Phase 3 BE COMPLETE study, which evaluated the...
Source: prnewswire.com